Phathom Pharmaceuticals Inc. (NASDAQ: PHAT): Think Like A Lender, Not An Investor

Phathom Pharmaceuticals Inc. (NASDAQ:PHAT) currently has a daily average trading volume of 381.60K but it saw 2998241 shares traded on Wednesday. With a market cap of 499.20M USD, stock’s current market price of $11.71 came falling about -10.41 while comparing to the previous closing price of $13.07. In past 52 weeks, the stock remained buoying in the range of price level as high as $14.45 and as low as $5.84. In the recent trading on the day, stock has struck highest price mark of $12.13 while lowest mark touched by it was $11.41.

Taking a look at 20-day trading activity of Phathom Pharmaceuticals Inc. (PHAT) gives us an average price of $12.25, while its current price level is -18.95% below from 52-week high level whereas it is 100.51% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $9.82 while that of 200 days or SMA-200 reads an average of $9.84. A closer look into the stock’s movement over the week reveals that its volatility is standing at 5.85% during that period while stretching the period over a month that increases to 7.43%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 49.80 which implies that the stock is in neutral territory.

Phathom Pharmaceuticals Inc. (PHAT)’s stock is currently under the radar of 7 analysts who are in consensus at a 12-month price target range of between $9.00 and $27.00 for company’s shares. The average price target assigned by the average number of analysts to a stock is a way to gauge worth of any stock in next 52 weeks. And in assigning price target to a stock, some analysts adopt a bearish approach by advocating lower-than-average price target which in this case is $9.00 while some adopt bullish approach by assigning higher-than-average price target which reads the price to top $27.00. Average price target assigned by them is $18.50 which highlights an upside potential of 36.7% for the stock over that period. And to attain the median price target of $18.50 assigned by those analysts, stock has to add about 36.7% of value to its current levels.

Data by FactSet Research shows that 7 analysts have issued their ratings for the stock. 0 of them are in opinions that stock is a Sell, while 0 are advising it as an Overweight. 6 analysts suggested the investors to Buy the stock while 1 advised them to Hold. Recommendations by all of those brokerages imply a consensus rating of Buy for the stock and that issued by Wall Street to investors is Strong Buy.

Over the week, PHAT’s stock price is moving -11.76% down while it is 14.80% when we observe its performance for the past one month. Year-to-date it is 4.37% up and over the past year, the stock is showing an upside performance of 39.24%.

The latest quarterly earnings report issued by the company was for quarter ended 3/30/2023, when its quarterly earnings per share (EPS) of -$0.89 beat the consensus estimate of -$1.26 for the same. The company is expected to be releasing its next quarterly report in 08/09/2023, for which analysts forecasted an EPS of -$1.04 while estimate for next year EPS is -$4.56. For PHAT, analysts are forecasting an EPS-growth rate of 9.70% for current year and estimate for EPS growth in next year is -19.10%.

Currently, Phathom Pharmaceuticals Inc.’s total number of outstanding shares is 42.35M with 21.52% of that held by the insiders while 70.57% of its common stock has been owned by the institutions. Company’s return on equity (ROE) at 392.80%. Stock’s beta reads 0.33. Its return on asset (ROA) is -107.60% on average.

A filing at the U.S. Securities and Exchange Commission revealed that Invesco Global Fund came shrinking its share ownership by -1.90% in the Phathom Pharmaceuticals Inc. (PHAT) decreasing its stake to 2.78% with control over 22544.0 shares in the company. As per SEC documents, Invesco Global Fund sought 1,165,676 of company’s common stock of worth $12.47 million as per recent closing price of the stock. Invesco Global Fund is not the only institutional holder which restructured its stake in Phathom Pharmaceuticals Inc., as Vanguard Total Stock Market ETF picked 636,452 shares of worth $6.81 million to bring its holdings to a total of 28318.0 shares. In the most recent quarter, iShares Russell 2000 ETF came cutting its stake by -1.44% in the company and now holds 0.51 million or 1.22% of the company’s stake having worth of about 5.49 million.